KPRX Bathi resik saben saham (EPS TTM) Kiora Pharmaceuticals

Geopolitical threats to Kiora Pharmaceuticals (KPRX) are minimal due to the stability of the US regulator. The current EPS TTM level visualizes these risks, where the -2.92 mark characterizes this parameter. Business resilience is based on the development of innovative KIO-301 molecular switches to combat blindness. High scientific authority in treating orphan eye pathologies confirms the company's status as a leading biopharmaceutical innovator.

KPRX Bathi resik saben saham sajrone patang kuartal pungkasan Kiora Pharmaceuticals (04.07.2022 - 15.11.2026)

Rincian metrik lan analitis perusahaan Kiora Pharmaceuticals (KPRX)

- rega saham lan prakiraan rega para ahli:

Kutipan saham Kiora Pharma|KPRX - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Kapitalisasi pasar Kiora Pharmaceuticals, Inc.|KPRX - Total Nilai Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham Kiora Pharmaceuticals|KPRX - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku kiorapharma.com|KPRX - Total Aset Perusahaan

- rincian utang lan likuiditas:

Total Utang marang Modal Kiora Pharmaceuticals|KPRX - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Kiora Pharma|KPRX - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Kiora Pharmaceuticals|KPRX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Kiora Pharmaceuticals|Indikator likuiditas cepet kiorapharma.com

- data bathi lan kelipatan valuasi:

KPRX - Bathi pungkasan|Bathi sing dikarepake Kiora Pharmaceuticals|KPRX - Kapitalisasi marang bathi resik|Pangali Forward P/E Kiora Pharmaceuticals, Inc.|KPRX - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Kiora Pharmaceuticals Inc.|KPRX - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Kiora Pharmaceuticals|KPRX - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan kiorapharma.com|KPRX - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Kiora Pharmaceuticals

- data total pendapatan lan volume dodolan:

KPRX - Pendapatan lan volume dodolan|Prakiraan volume dodolan Kiora Pharmaceuticals, Inc.|KPRX - Kapitalisasi marang pendapatan|Multiplikator Forward P/S Kiora Pharmaceuticals, Inc.|KPRX - Wutah pendapatan taun lumaku

Analisis dhasar perusahaan:KPRX - Kiora Pharma

The development of ophthalmological drugs in specialized laboratories at Kiora Pharmaceuticals (KPRX) requires significant capital expenditures. The rolling 12-month EPS metric illustrates the efficiency of these resource allocations per share. This metric aggregates net income over four quarters, excluding the impact of the total shares outstanding. An upward trend confirms the monetization of research, while stagnation signals a high-cost period. This indicator determines the real return on investor capital.

Perusahaan pesaing